RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Kluyveromyces marxianus 균주를 이용한 3-Hydroxypropionic acid 생산

        박재범(Jae-Bum Park),강경곤(Kyoung-Gon Kang),권덕호(Deok-Ho Kwon),하석진(Suk-Jin Ha) 한국생물공학회 2020 KSBB Journal Vol.35 No.4

        Thermotolerant yeast, Kluyveromyces marxianus was applied for the production of 3-hydroxypropionic acid (3-HP), which is mainly used as a raw material for biodegradable polymers. The MCR (malonyl-CoA reductase) gene originated from the Chloroflexus aurantiacus strain was introduced into the engineered K. marxianus 17555-JBP2 strain showing improved xylose utilization in the previous study to develop the engineered K. marxianus JBP2_MCR strain. At 40℃, K. marxianus JBP2_MCR strain produced 0.14±0.00 g/L of 3-HP using xylose as a sole carbon source. As a result of measuring the enzymatic activity of malonyl-CoA reductase, the engineered K. marxianus JBP2_MCR strain exhibited 4.71 times higher MCR enzymatic activity than the parent strain. When 1.28 g/L malonyl-CoA was added into media, 1.58±0.18 g/L of 3-HP was produced by K. marxianus JBP2_MCR strain for 120 h.

      • KCI등재

        항체-약물 접합체의 개발 및 최신 동향

        홍유동(Yudong Hong),강경곤(Kyoung-Gon Kang),정재윤(Jae-Youn Jung),하석진(Suk-Jin Ha),임광석(Kwang Suk Lim) 한국생물공학회 2021 KSBB Journal Vol.36 No.2

        Biopharmaceutical drugs have strong therapeutic effect in various diseases such as autoimmune diseases, rheumatism and cancer due to their target specific recognition and low side effects. In particular, the most representative antibodies among biopharmaceuticals are widely used for targeted drug delivery, diagnosis and treatment. Moreover, antibody-drug conjugate (ADC) have been developed by many researchers and biopharmaceutical companies. An antibody-drug conjugate, one of the new bio anticancer drugs is composed of an antibody, cytotoxic drug and chemical linker. Antibodies accurately recognize the target cancer, and drugs induce apoptosis or death of the cancer cells. Linkers stably connects the antibody and drug until ADC go to the target cancer cells. In order to develop an ADC, it is important to correctly configure each component. Recently, the 9th ADC was approved by food and drug administration (FDA) and a lot of development of new ADC is underway. The development of ADC is expected through the introduction of new antibodies including bi-specific and drugs with new anticancer mechanisms.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼